Tag Archives: @JAMA_current

NCCIH Study Finds Marked Increase in Complementary Health Approaches Among US Adults, Including for Pain Management

Posted on by

PainRelief.com Interview with:
Richard L. Nahin, Ph.D., M.P.H
Lead Epidemiologist
National Center for Complementary and Integration Health
NCCIH

PainRelief.com: What is the background for this study?

Response: Millions of US adults use complementary health approaches (CHAs) each year. CHAs are health approaches typically not part of conventional medical care or with origins outside of Western medicine that are used together with conventional medical practice.

Some of the most well-known complementary health approaches include meditation, acupuncture, and yoga. While the safety and efficacy of many of these approaches previously lacked rigorous clinical trials, the last two decades saw an increase in evidence supporting the use of select approaches to manage health and pain.

Continue reading →

JAMA Study Finds Clinicians Not Maximizing Opportunities to Initiate Buprenorphine Treatment For Patients With Opioid Addiction

Posted on by

PainRelief.com Interview with:
Kao-Ping Chua, MD, PhD
Susan B. Meister Child Health Evaluation and Research Center
Department of Pediatrics, University of Michigan Medical School
Ann Arbor MI 48109

Kao-Ping Chua

PainRelief.com: What is the background for this study?

Response: Opioid overdose deaths are at a record high in the U.S. Many opioid overdose deaths can be prevented by medications for opioid use disorder, such as buprenorphine, a drug that can prescribed in office settings. However, buprenorphine cannot prevent opioid overdose deaths if patients are never started on the medication or only stay on the medication for a short time. For that reason, rates of buprenorphine initiation and retention are critical metrics for measuring how well the U.S. health care system is responding to the opioid epidemic.

At the time we started our study, several other research groups had evaluated U.S. rates of buprenorphine initiation and retention using data through 2020. However, more recent national data were lacking. We felt that this was an important knowledge gap given the many changes in society that have occurred since 2020. For example, it was possible that the relaxation of social distancing measures during 2021 and 2022 might have reduced barriers to health care visits, thereby increasing opportunities to initiate treatment for opioid addiction with buprenorphine.

Pages: 1 2

Wake Forest Study Finds Diet and Exercise Can Lead to Pain Relief from Knee Arthritis

Posted on by

PainRelief.com Interview with:
Stephen P. Messier, Ph.D.
Professor J.B. Snow Biomechanics Laboratory
Department of Health and Exercise Science
Worrell Professional Center
Wake Forest University
Winston Salem, NC 27109

Dr. Messier

PainRelief.com: What is the background for this study?   What are the main findings?

Response: Some weight loss and exercise programs that have been successful in academic center-based trials have not been evaluated in community settings.  The results showed that among patients with knee osteoarthritis and overweight or obesity, diet and exercise compared with an attention control led to statistically significant differences in pain, function, mobility, body weight, waist circumference, and quality of life.

Pages: 1 2

Novel Protocol Reduced Use of Opioid Pain Relievers After Knee and Shoulder Surgeries

Posted on by

PainRelief.com Interview with:
Nicole Simunovic, MSc
On behalf of the NO PAin Principal Investigators

PainRelief.com: What is the background for this study?

Response: Orthopaedic surgeons prescribe more opioids than any other type of surgeon in North America. Opioids have the potential to be highly addictive and can cause serious harm or even death if taken in excess. The goal of our clinical study was to determine if an opioid sparing approach to postoperative pain management was safe and effective in patients undergoing arthroscopic knee and shoulder surgery.

Pages: 1 2

Infused VYEPTI Provided Pain Relief When Initiated During a Migraine Attack

Posted on by

PainRelief.com Interview with:
Roger Cady, MD
VP Neurology
Lundbeck Pharmaceutical
La Jolla Research Center
San Diego, CA 92121

PainRelief.com:  What is the background for this study? 

Response: The RELIEF study evaluated how preventive migraine candidates may benefit from a VYEPTI infusion during an active migraine attack when administered within 1 to 6 hours of a moderate to severe migraine attack. VYEPTI is the first and only intravenous (IV) infusion approved for the preventive treatment of migraine in adults.

Continue reading →